文献速递结核与非结核分枝杆菌

阿奇霉素作为肺结核宿主导向治疗:一项随机先导试验

Azithromycin as Host-Directed Therapy for Pulmonary Tuberculosis: A Randomized Pilot Trial.
PubMed 文献 · J Infect Dis · 2025-01-01

该开放标签随机对照先导试验纳入28例药物敏感肺结核成人患者,在抗结核治疗开始4周内随机接受标准治疗或加用阿奇霉素250 mg口服每日一次共28天。阿奇霉素组血中IP-10和C4M下降更显著,痰中中性粒细胞、中性粒细胞弹性蛋白酶和TGF-β显著降低,其他指标无显著影响,治疗看似安全。

要点

  • 阿奇霉素250 mg每日一次加标准抗结核治疗28天,可显著增强血中IP-10和C4M的下降。
  • 阿奇霉素组痰中性粒细胞、中性粒细胞弹性蛋白酶和TGF-β显著降低。
  • 其他参数未见显著影响,阿奇霉素治疗看似安全。

核心结论

  • 在标准抗结核治疗基础上加用阿奇霉素似乎可减轻肺结核患者过度的中性粒细胞性炎症。

研究设计与样本

  • 开放标签、随机、对照先导试验,纳入28例年龄大于18岁的药物敏感肺结核成人患者,在开始抗结核治疗4周内入组。
  • 患者随机接受标准抗结核治疗或阿奇霉素250 mg口服每日一次加标准治疗共28天,两组各有12例完成试验。

主要发现

  • 血中结核标志物干扰素-γ诱导蛋白-10(IP-10)下降幅度:标准治疗加阿奇霉素组-38% vs 标准治疗组-24%(P < .05)。
  • 血中IV型胶原降解产物C4M下降幅度:标准治疗加阿奇霉素组-26% vs 标准治疗组-11%(P < .05)。
  • 痰中中性粒细胞变化:标准治疗加阿奇霉素组-24% vs 标准治疗组0%(P < .001)。
  • 痰中中性粒细胞弹性蛋白酶变化:标准治疗加阿奇霉素组-88% vs 标准治疗组75%(P < .01)。
  • 痰中转化生长因子-β变化:标准治疗加阿奇霉素组-86% vs 标准治疗组-68%(P < .05);其他参数未见显著影响。

关键数值与推荐

  • 阿奇霉素用法为250 mg口服每日一次,共28天,加于标准抗结核治疗。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjunctive host-directed therapies that modulate host immune responses to reduce excessive inflammation and prevent tissue damage in tuberculosis are being investigated. Macrolides, including azithromycin, were shown to possess anti-inflammatory and immune-modulatory effects in addition to their antibacterial effects. In the current trial, we investigated whether azithromycin enhances resolution of systemic and pulmonary inflammation and decreases extracellular matrix-related tissue turnover in tuberculosis patients. METHODS: An open-label, randomized, controlled trial was performed. Adult patients with drug-susceptible, pulmonary tuberculosis aged above 18 years were randomly assigned to receive standard antituberculosis care or azithromycin 250 mg orally once daily in addition to standard care (SOC) for 28 days. RESULTS: Twenty-eight patients were included within 4 weeks after initiating antituberculosis treatment. Twelve patients in both arms completed the trial. Participants were mostly young, male, had a history of smoking, and had no comorbidities. No differences in baseline characteristics were observed between the study arms. In blood, azithromycin treatment significantly enhanced the reduction of the tuberculosis marker interferon-γ-induced protein-10 (SOC plus azithromycin, -38% vs SOC alone, -24% vs SOC, P < .05) and the collagen type IV degradation product C4M (-26% vs -11%, P < .05). In sputum, treatment with azithromycin significantly reduced neutrophils (-24% vs 0%, P < .001), neutrophil elastase (-88% vs 75%, P < .01), and transforming growth factor-β (-86% vs -68%, P < .05). No significant effects were observed on other parameters. Treatment with azithromycin appeared to be safe. CONCLUSIONS: The addition of azithromycin to standard antituberculosis treatment appears to diminish excess neutrophilic inflammation in patients with pulmonary tuberculosis. Clinical Trials Registration. NCT03160638.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Dekkers BGJ, Kerstjens HAM, Breisnes HW, et al. Azithromycin as Host-Directed Therapy for Pulmonary Tuberculosis: A Randomized Pilot Trial. J Infect Dis. 2025. PMID: 39932906. doi:10.1093/infdis/jiaf069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。